From a quick review, in terms of cancers being tar
Post# of 145482
![](/assets/46931549/no_avatar_available_thumb.jpg)
Quote:
From a quick review, in terms of cancers being targeted (mTNBC and Prostate, among others) and possible FDA filings, Nantkwest l (NK) has some drugs in their pipeline that are just ahead of Leronlimab and are showing similar results.
Their stock price went from $1 to $7 in the last six weeks. Could experts like ohm20 comment on this from a competitor perspective?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)